Trial Outcomes & Findings for A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC) (NCT NCT03693937)

NCT ID: NCT03693937

Last Updated: 2019-07-05

Results Overview

NMSC cure rate will be calculated as the percentage of lesions that attained complete cure following SRT-100 treatment completion.

Recruitment status

COMPLETED

Target enrollment

776 participants

Primary outcome timeframe

5 years

Results posted on

2019-07-05

Participant Flow

Participant milestones

Participant milestones
Measure
Non-Melanoma Skin Cancers (NMSCs)
Non-Melanoma Skin Cancers (NMSCs) treated with SRT-100 therapy.
Overall Study
STARTED
776
Overall Study
COMPLETED
776
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Non-Melanoma Skin Cancers (NMSCs)
n=516 Participants
Non-Melanoma Skin Cancers (NMSCs) treated with SRT-100 therapy.
Age, Continuous
78.94 years
STANDARD_DEVIATION 8.89 • n=99 Participants
Sex: Female, Male
Female
223 Participants
n=99 Participants
Sex: Female, Male
Male
293 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Participant Race · Hispanic or Latino
0 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Participant Race · Not Hispanic or Latino
516 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Participant Race · Unknown or Not Reported
0 Participants
n=99 Participants
Region of Enrollment
United States
516 Participants
n=99 Participants

PRIMARY outcome

Timeframe: 5 years

NMSC cure rate will be calculated as the percentage of lesions that attained complete cure following SRT-100 treatment completion.

Outcome measures

Outcome measures
Measure
Non-Melanoma Skin Cancers (NMSCs)
n=760 lesions
Non-Melanoma Skin Cancers (NMSCs) treated with SRT-100 therapy.
Cure Rate
751 lesions

Adverse Events

Non-Melanoma Skin Cancers (NMSCs)

Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Non-Melanoma Skin Cancers (NMSCs)
n=776 participants at risk
Non-Melanoma Skin Cancers (NMSCs) treated with SRT-100 therapy.
Skin and subcutaneous tissue disorders
Radiation Dermatitis
0.77%
6/776 • 5 years

Additional Information

Isabelle Raymond

Sensus Healthcare

Phone: 561-922-5808

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place